Legend Biotech Corporation American Depositary Shares (LEGN) Stock
Key stats
- Market cap
- $3.79B
- Price / Earnings ratio
- -13196.3x
- EPS (TTM)
- -$0.02
- Volume
- Loading
- 52-week high
- $37.50
- 52-week low
- $16.24
Source: third-party data provider, as of November 13, 2026
Compare with LEGN
Recent news

LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
LEGN

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
LEGN

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
LEGN

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
LEGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.60
- MACD 12/26/9
- 0.64
- EMA 9 of MACD
- 0.73
- MACD histogram
- -0.09
- SMA 50
- $19.72
- Price below SMA 50
- EMA 50
- $20.59
- Price below EMA 50
- SMA 200
- $22.19
- Price below SMA 200
- EMA 200
- $21.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
LEGN

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
LEGN

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
LEGN

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
LEGN

Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech taps Novartis veteran Zhang as CEO
LEGN

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
LEGN

Legend Biotech Q2 Earnings Call Highlights
Legend Biotech Q2 Earnings Call Highlights
LEGN

LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset
LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset
LEGN

Legend's experimental cell therapy shows promise in blood cancer patients
Legend's experimental cell therapy shows promise in blood cancer patients
LEGN

Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
LEGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Legend Biotech Corporation American Depositary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Carlos Santos Garcia | Chief Financial Officer | 1972 |
| Ms. Ananda Elizabeth Martin Esq., J.D. | Global Compliance Officer | 1974 |
| Mr. Robert Staloff | General Counsel | — |
| Dr. Ying Huang Ph.D. | Advisor | 1973 |
| Dr. Yuhong Qiu Ph.D. | Interim Head of Research & Development and Senior VP of Regulatory Affairs | — |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.60
- MACD 12/26/9
- 0.64
- EMA 9 of MACD
- 0.73
- MACD histogram
- -0.09
- SMA 50
- $19.72
- Price below SMA 50
- EMA 50
- $20.59
- Price below EMA 50
- SMA 200
- $22.19
- Price below SMA 200
- EMA 200
- $21.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $46.17
- High
- $65.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.9 | -6.5 | ||||||||||
| 2022 | -11.5 | -7.9 | -4.5 | +2.7 | +0.9 | +29.0 | -15.4 | +3.1 | -12.8 | +23.7 | +1.0 | +0.3 |
| 2023 | +3.7 | -10.8 | +2.3 | +46.0 | -4.6 | +8.5 | +9.7 | -7.0 | -6.2 | +1.8 | -9.0 | +0.3 |
| 2024 | -6.8 | +15.9 | -14.4 | -23.6 | -9.0 | +10.6 | +22.5 | +4.6 | -15.0 | -5.2 | -5.2 | -24.9 |
| 2025 | +9.7 | -6.2 | +2.9 | +10.9 | -14.8 | +21.0 | +7.7 | -10.5 | -4.7 | -0.8 | -13.8 | -19.0 |
| 2026 | -18.6 | +10.8 | -1.9 | +23.5 | +15.1 | +13.2 | -37.9 | +9.3 | -5.9 | +12.0 | -3.3 |



